Precision Oncology is the exclusive distributor for Caris Molecular Intelligence® (CMI) in Australia and New Zealand. Caris is the most experienced and accredited molecular tumour profiling service in the world. Caris has been tumour profiling since 2008 and has profiled more than 140,000 tumours for over 7,500 oncologists from 81 countries. Treatment decisions informed with Caris Molecular Intelligence tumour profiling improve clinical outcomes.
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation, and is the world’s leading immunotherapy diagnostic expert. Caris Molecular Intelligence®, the company’s Comprehensive Genomic Profiling Plus (CGP+) molecular testing service, assesses DNA, RNA and proteins, including microsatellite instability (MSI), tumour mutational burden (TMB) and PD-L1, to reveal a molecular blueprint to guide more precise and personalised treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com.
When you order with Precision Oncology we organise the whole process to get your sample from the lab in Australia or NZ to Caris Life Sciences’ lab in the US, and the report back to your oncologist in under 3 weeks. The results from profiling are combined with the very latest cancer target (biomarker) research to determine the treatments that are likely to work against your cancer. Our package includes highly-accredited molecular profiling, service logistics, oncologist report and clinical trials connector.